Skip to main content
. 2010;4(2):20–28. doi: 10.4314/ajid.v4i2.55149

Figure 7.

Figure 7

Meta-analysis of Artesunate + Amodiaquine (AS+AQ) Versus Arthemeter-Lumefantrine (AL) according to country.

All studies that satisfied the inclusion criteria were included in this analysis. The outcome measure of interest (day 28 parasitological failure) is not clinically desirable; therefore, the right side of the graph favours Arthemeter-Lumefantrine.